RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer
SEOUL, South Korea — The combination of avutometinib and defactinib achieved “exceptionally” high response rates in heavily pretreated patients with recurrent low-grade serous ovarian cancer (LGSOC), according to the ENGOT-ov60/GOG-3052/RAMP 201 trial. Moreover, responses were consistently high no matter how many previous lines of therapy patients received prior to study entry, reported Rachel N. Grisham […]